Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise (NASDAQ:PBYI)

seekingalpha.com · 2026-09-08

NERLYNX gives PBYI an established revenue stream that can support alisertib’s development into a potential second oncology franchise.

TickrTrends take: Puma Biotechnology's reliance on NERLYNX revenue to support development of additional oncology programs occurs within a context where TickrTrends currently assesses the stock as overvalued. Investors monitoring the company's valuation should track whether new oncology pipeline progress can justify the current market price or whether execution risks may validate the overvalued assessment. The Healthcare sector backdrop suggests scrutiny of both NERLYNX's sustained commercial performance and the timeline and costs associated with bringing next-generation oncology candidates to market.

Read the full story at seekingalpha.com →